However, in the GeparNuevo trial, higher pCR rates were observed in patients with PD-L1-positive tumors regardless of the treatment arm, with significant differences when considering the expression of PD-L1 on tumor cells in the durvalumab arm and on immune cells in the placebo arm [24,58] (Table S2). This evidence concerns the gene CD274 and neoplasm.